Last reviewed · How we verify
Monofer
At a glance
| Generic name | Monofer |
|---|---|
| Also known as | Ferinject, Cosmofer, Venofer, isomaltoside |
| Sponsor | Pharmacosmos A/S |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
- The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery (PHASE4)
- Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia (PHASE3)
- Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients (PHASE4)
- IV Iron-induced Hypophosphatemia After RYGB (PHASE4)
- Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer (PHASE3)
- The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life (PHASE4)
- The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monofer CI brief — competitive landscape report
- Monofer updates RSS · CI watch RSS
- Pharmacosmos A/S portfolio CI